Ignite Creation Date:
2024-07-17 @ 10:46 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500299
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-06-13
Brief Title:
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Sponsor:
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Organization:
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is a multicenter randomized double-blind placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults
Detailed Description:
This multicenter randomized double-blind placebo-controlled phase II clinical trial aims to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults Participants with a BMI between 24 and 40 will be include A total of 180 participants will be randomized in a 1111 ratio to receive different doses of HDM1002 or placebo Following the screening period to confirm eligibility up to 2-weeks the study will consist of a treatment period will be 12 weeks followed by an approximate 4-week follow-up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None